• AYA YASEEN MAHMOOD ALABDALI Department of Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, UCSI University Kuala Lumpur (South Wing), No. 1, Jalan Menara Gading, UCSI Heights 56000 Cheras, Kuala Lumpur, Malaysia
  • SASIKALA CHINNAPPAN Department of Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, UCSI University Kuala Lumpur (South Wing), No. 1, Jalan Menara Gading, UCSI Heights 56000 Cheras, Kuala Lumpur, Malaysia
  • BASMA M. ABD RAZIK Department of Pharmaceutical Chemistry, College of Pharmacy, Mustansiriyah University, 10001, Baghdad, Iraq
  • MOGANA R. Department of Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, UCSI University Kuala Lumpur (South Wing), No. 1, Jalan Menara Gading, UCSI Heights 56000 Cheras, Kuala Lumpur, Malaysia
  • SHAIK IBRAHIM KHALIVULLA Department of Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, UCSI University Kuala Lumpur (South Wing), No. 1, Jalan Menara Gading, UCSI Heights 56000 Cheras, Kuala Lumpur, Malaysia
  • RAHMAN H. Department of Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, UCSI University Kuala Lumpur (South Wing), No. 1, Jalan Menara Gading, UCSI Heights 56000 Cheras, Kuala Lumpur, Malaysia
  • LAITH H. SAMEIN The University of Mashreq, College of Pharmacy, Baghdad, Iraq



Corona virus disease (COVID-19), Organ failure, SAR-CoV-2, Cardiovascular system, Kidney, Lungs


COVID-19 is a highly contagious disease caused by Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2); which is a novel single-stranded positive RNA infection which consist of cytokines that activate the pathogenic systems that cause high respiratory pain condition, and adversely affect on multiple body organ in humans as per their immunity standards to fight against the virus. SARS-CoV-2 enters the host cell through Angiotensin-Converting Enzyme 2 (ACE 2). ACE 2 is a sub-part of the Renin-Aldosterone Angiotensin System (RAAS), intelligently communicated in the body's kidney, heart, lungs, and malignant tissues. The malfunctioning of RAAS in the body leads to hypertension, cardiovascular sicknesses, endocrine system and negatively affects a brain-body communication channel. Treatments on the RAAS structure, 'thiazolidinedione's and smoking, toxemia, kidney, lungs disorder due to the SARS-CoV-2 attack on the host cell and notice the behavioral changes of body organs the arrival of cytokines that causes multi-organ damage. This paper involves the study of the effects of coronavirus disease on multiple body-organ injuries.


Download data is not yet available.


Lian J, Jin X, Hao S, Jia H, Cai H, Zhang X, et al. Epidemiological, clinical, and virological characteristics of 465 hospitalized cases of coronavirus disease 2019 (COVID-19) from Zhejiang province in China. Influenza Other Respiratory Viruses 2020;14:564-74.

Hoffmann M, Kleine Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271-80. e8.

Klein S, Cortese M, Winter SL, Wachsmuth Melm M, Neufeldt CJ, Cerikan B, et al. SARS-CoV-2 structure and replication characterized by in situ cryo-electron tomography. Nature Communications 2020;11:1-10.

Navdeep K, Simranpreet K, Manjinder K. A review on the fifth pandemic: coronavirus. Asian J Pharm Clin Res 2020;13:25-31.

Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA 2020;323:1545-6.

Neela B, Jakkula S, Gaur RP. Corticosteroids and secondary infections: an insight into coronavirus disease-2019. Asian J Pharm Clin Res 2021;14:36-47.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020;323:1061-9.

Dariya B, Nagaraju GP. Understanding novel COVID-19: its impact on organ failure and risk assessment for diabetic and cancer patients. Cytokine Growth Factor Rev 2020;53:43-52.

V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol 2021;19:155-70.

Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cumming DA. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis 2009;9:291-300.

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunologic features in severe and moderate forms of coronavirus disease 2019. J Clin Invest 2020;130:2620-9.

Zheng HY, Zhang M, Yang CX, Zhang N, Wang XC, Yang XP, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol 2020;17:541-3.

Libraty DH, O'Neil KM, Baker LM, Acosta LP, Olveda RM. Human CD4+memory T-lymphocyte responses to SARS coronavirus infection. Virology 2007;368:317-21.

Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol 2011;85:12201-15.

Thevarajan I, Nguyen TH, Koutsakos M, Druce J, Caly L, Van de Sandt CE, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med 2020;26:453-5.

Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, et al. Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality. Am J Pathol 2020;190:2290-303.

Joseph SK, MA A, Thomas S, Nair SC. State-of-the-art nanotechnology-based drug delivery strategies to combat covid-19. Int J Appl Pharm 2021;13:18-29.

Hafiane A. SARS-CoV-2 and the cardiovascular system. Clin Chim Acta 2020;510:311-6.

Duramad P, Tager IB, Holland NT. Cytokines and other immunological biomarkers in children's environmental health studies. Toxicol Lett 2007;172:48-59.

Lyons C, Callaghan M. The use of high‐flow nasal oxygen in COVID‐19. Anaesthesia 2020;75:843-7.

Ferrando C, Mellado Artigas R, Gea A, Arruti E, Aldecoa C, Adalia R, et al. Awake prone positioning does not reduce the risk of intubation in COVID-19 treated with high-flow nasal oxygen therapy: a multicenter, adjusted cohort study. Critical Care 2020;24:1-11.

Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Annals Int Med 2020;172:577-82.

Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al. A single-center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. Kidney Int 2020;97:1083-8.

Hultstöm M, Von Seth M, Frithiof R. Hyperreninemia and low total body water may contribute to acute kidney injury in coronavirus disease 2019 patients in intensive care. J Hypertension 2020. DOI:10.1097/HJH.0000000000002531

Rahimi H, Tehranchinia Z. A comprehensive review of cutaneous manifestations associated with COVID-19. BioMed Res Int 2020;2020:1236520.

Davies P, Evans C, Kanthimathinathan HK, Lillie J, Brierley J, Waters G, et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. Lancet Child Adolescent Health 2020;4:669-77.

Parikh CR, Han G. Variation in performance of kidney injury biomarkers due to cause of acute kidney injury. Am J Kidney Diseases 2013;62:1023-6.

Wang L, Li X, Chen H, Yan S, Li D, Li Y, et al. Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China. Am J Nephrol 2020;51:343-8.

Alberca RW, Aoki V, Sato MN. COVID-19 and HIV: case reports of 2 co-infected patients with different disease courses. World Academy Sci J 2021;3:1-4.

Navik U, Bhatti J, Sheth V, Jawalekar S, Bhatti G, Kalra S. Multi-organ failure in COVID-19 patients: a possible mechanistic approach. Authorea Preprints 2020. DOI:10.22541/au.159110399.94076751

Mehra MR, Desai SS, Kuy SR, Henry TD, Patel AN. Retraction: cardiovascular disease, drug therapy, and mortality in covid-19. New England J Med 2020;382:2582.

Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and cardiovascular disease. Circulation 2020;141:1648-55.

Guo Q, Feng X, Zhou Y. Potential impact of brain and heart interaction on cardiovascular system in covid-19 patients. Authorea Preprints 2020. DOI:10.22541/au.159373155.50189648

Hangargekar CB, Quazi RS, Joshi AA. A review on covid-19-a global battle between life and death. Int J Curr Pharm Res 2020;12:19-24.

Matsushita K, Marchandot B, Jesel L, Ohlmann P, Morel O. Impact of COVID-19 on the cardiovascular system: a review. J Clin Med 2020;9:1407.

Yoganathan A, Sajjad M, Harky A. Cardiovascular disease and the impact of COVID-19. Authorea Preprints 2020;35:2113.

Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017:a systematic analysis for the global burden of disease study 2017. Lancet 2018;392:1736-88.

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA 2020;323:1239-42.

Fadini G, Morieri M, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest 2020;43:867-9.

Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019-united states. MMWR Morb Mortal Wkly Rep 2020;69:382-6.

Tinelli G, Sica S, Guarnera G, Pitocco D, Tshomba Y. Wound care during COVID-19 pandemic. Annals Vascular Surgery 2020;68:93-4.

Rao S, Lau A, So HC. Exploring diseases/traits and blood proteins causally related to the expression of ACE2, the putative receptor of SARS-CoV-2: A mendelian randomization analysis highlights tentative relevance of diabetes-related traits. Diabetes Care 2020;43:1416-26.

AlGhatrif M, Cingolani O, Lakatta EG. The dilemma of coronavirus disease 2019, aging, and cardiovascular disease: insights from cardiovascular aging science. JAMA Cardiol 2020;5:747-8.

Fernandez C, Rysa J, Almgren P, Nilsson J, Engstrom G, Orho Melander M, et al. Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality. J Int Med 2018;284:377-87.

Maddaloni E, Buzzetti R. Covid‐19 and diabetes mellitus: unveiling the interaction of two pandemics. Diabetes/Metab Res Rev 2020;31:e33213321.

Kulcsar KA, Coleman CM, Beck SE, Frieman MB. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight 2019;4:e131774.

Yang Y, Zhong W, Tian Y, Xie C, Fu X, Zhou H. The effect of diabetes on mortality of COVID-19: a protocol for systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e20913.

Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 infection in children. New England J Med 2020;382:1663-5.

Meena J, Yadav J, Saini L, Yadav A, Kumar J. Clinical features and outcome of SARS-CoV-2 infection in children: a systematic review and meta-analysis. Indian Pediatrics 2020;57:820-6.

Gotzinger F, Santiago Garcia B, Noguera Julian A, Lanaspa M, Lancella L, Carducci FIC, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolescent Health 2020;4:653-61.

Novel CPERE. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liuxingbingxue Zazhi 2020;41:145-51.

Ludvigsson JF. Systematic review of COVID‐19 in children shows milder cases and a better prognosis than adults. Acta Paediatrica 2020;109:1088-95.

Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 among children in China. Pediatrics 2020;145.

Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. New England J Med; 2020.

Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics 2020. DOI:10.1542/peds.2020-0702

Luo Y, Yin K. Management of pregnant women infected with COVID-19. Lancet Infectious Diseases 2020;20:513-4.

Hayakawa K, Mukunoki H. Impacts of covid-19 on international trade: evidence from the first quarter of 2020. Institute of Developing Economies, Japan External Trade Organization (JETRO); 2020.

Navidinia M, Goudarzi M. The main associated symptoms related to covid-19 (Coronavirus disease 2019) among pediatric patients. Arch Adv Biosci 2020;11:64-72.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. New England J Med 2020;382:727-33.

Bayramoglu Z, Canıpek E, Comert RG, Gasimli N, Kaba O, Yanartaş MS, et al. Imaging features of pediatric covid-19 on chest radiography and chest CT: A retrospective, single-center study. Academic Radiol 2020;28:18-27.

Cheng Y, Wong R, Soo Y, Wong W, Lee C, Ng M, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Inf Diseases 2005;24:44-6.

Koyama T, Weeraratne D, Snowdon JL, Parida L. Emergence of drift variants that may affect COVID-19 vaccine development and antibody treatment. Pathogens 2020;9:324.

Klok F, Kruip M, Van der Meer N, Arbous M, Gommers D, Kant K, et al. Incidence of thrombotic complications in critically ill ICU patients with covid-19. Thrombosis Res 2020;191:145-7.

Bhattacharyya R, Iyer P, Phua GC, Lee JH. The interplay between coagulation and inflammation pathways in COVID-19-associated respiratory failure: a narrative review. Pulm Ther 2020;6:215-31.

Gombart AF. The vitamin D–antimicrobial peptide pathway and its role in protection against infection. Future Microbiol 2009;4:1151-65.

Pillat MM, Kruger A, Guimaraes LMF, Lameu C, de Souza EE, Wrenger C, et al. Insights in chloroquine action: perspectives and implications in Malaria and covid‐19. Cytometry Part A 2020;97:872-81.

Chen Y, Chen L, Deng Q, Zhang G, Wu K, Ni L, et al. The presence of SARS‐CoV‐2 RNA in the feces of COVID‐19 patients. J Med Virol 2020;92:833-40.

Campbell JI, Ocwieja KE, Nakamura MM. A call for pediatric covid-19 clinical trials. Pediatrics 2020;146. 10.1542/peds.2020-1081.

Group SC-G. Genomewide association study of severe Covid-19 with respiratory failure. New England J Med 2020;383:1522-34.

Luo Y, Trevathan E, Qian Z, Li Y, Li J, Xiao W, et al. Asymptomatic SARS-CoV-2 infection in household contacts of a healthcare provider, Wuhan, China. Emerging Infect Dis 2020;26:1930.

Yan Y, Zou Z, Sun Y, Li X, Xu KF, Wei Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res 2013;23:300-2.

Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon-beta against MERS-CoV. Nat Commun 2020;11:1-14.

Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020.

Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering 2020;6:1192-8.

Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Bioscience Trends 2020;14:64-8.

Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerging Infect Dis 2016;22:1554.

Amirian ES. Potential fecal transmission of SARS-CoV-2: current evidence and implications for public health. Int J Inf Diseases 2020;95:363-70.

Lin S, Shen R, Guo X. Molecular modeling evaluation of the binding abilities of ritonavir and lopinavir to Wuhan pneumonia coronavirus proteases. bioRxiv 2020.

Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al. Lopinavir–ritonavir versus nelfinavir for the initial treatment of HIV infection. New England J Med 2002;346:2039-46.

Pulido F, Arribas JR, Delgado R, Cabrero E, Gonzalez Garcia J, Perez Elias MJ, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 2008;22:F1-F9.

Chu C, Cheng V, Hung I, Wong M, Chan K, Chan K, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004;59:252-6.

Zhang J, Zhou L, Yang Y, Peng W, Wang W, Chen X. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet Res Med 2020;8:e11-e2.

Torjesen I. Covid-19: hydroxychloroquine does not benefit hospitalised patients, UK trial finds. Br Med J 2020;369.

Davis MR, McCreary EK, Pogue JM. That escalated quickly: remdesivir's place in therapy for covid-19. J Infect Dis Ther 2020;9:525-36.

Paladugu S, Donato AA. Remdesivir improved time to recovery in adults hospitalized with covid-19 and lower respiratory tract involvement. Ann Intern Med 2020;173:JC4.

Bouazza N, Treluyer JM, Foissac F, Mentre F, Taburet AM, Guedj J, et al. Favipiravir for children with Ebola. Lancet 2015;385:603-4.

Jones B, Ma E, Peiris J, Wong P, Ho J, Lam B, et al. Prolonged disturbances of in vitro cytokine production in patients with severe acute respiratory syndrome (SARS) treated with ribavirin and steroids. Clin Exp Immunol 2004;135:467-73.

Griffin S. Covid-19: lopinavir-ritonavir does not benefit hospitalised patients, UK trial finds. Br Med J Publishing Group 2020;370:m2650.

Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-a possible reference for coronavirus disease‐19 treatment option. J Med Virol 2020;92:556-63.



How to Cite

MAHMOOD ALABDALI, A. Y., CHINNAPPAN, S., ABD RAZIK, B. M., R., M., KHALIVULLA, S. I., H., R., & SAMEIN, L. H. (2021). IMPACT OF COVID-19 ON MULTIPLE BODY ORGAN FAILURE: A REVIEW. International Journal of Applied Pharmaceutics, 13(5), 54–59.



Review Article(s)